ProfileGDS5678 / 1435775_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 61% 61% 59% 63% 62% 61% 62% 60% 65% 67% 63% 65% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5390658
GSM967853U87-EV human glioblastoma xenograft - Control 23.6555961
GSM967854U87-EV human glioblastoma xenograft - Control 33.6566661
GSM967855U87-EV human glioblastoma xenograft - Control 43.4739759
GSM967856U87-EV human glioblastoma xenograft - Control 53.7613863
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7945562
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.734761
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6889662
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6004660
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8803265
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0242267
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7578463
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9163465
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7483263